UBS AM
IMNM icon

UBS AM’s Immunome IMNM Stock Holding History

UBS AM’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
188,636
+1,625
+0.9% +$34.8K ﹤0.01% 1717
2026
Q1 		$4.09M Buy
187,011
+63,262
+51% +$1.41M ﹤0.01% 1667
2025
Q4 		$2.66M Buy
123,749
+11,451
+10% +$201K ﹤0.01% 1761
2025
Q3 		$1.32M Sell
112,298
-74,400
-40% -$740K ﹤0.01% 1910
2025
Q2 		$1.74M Buy
186,698
+108,354
+138% +$888K ﹤0.01% 2204
2025
Q1 		$527K Buy
78,344
+20,151
+35% +$193K ﹤0.01% 2493
2024
Q4 		$618K Buy
58,193
+14,328
+33% +$173K ﹤0.01% 2516
2024
Q3 		$641K Sell
43,865
-8,189
-16% -$116K ﹤0.01% 2577
2024
Q2 		$630K Buy
52,054
+40,354
+345% +$631K ﹤0.01% 2561
2024
Q1 		$289K Buy
+11,700
New +$237K ﹤0.01% 2406

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

UBS AM's IMNM Position: Q2 2026 in Review

UBS AM increased its Immunome (IMNM) stake by 0.87% in Q2 2026, buying an estimated $34.8K and bringing the position to 188,636 shares worth $4M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

UBS AM first reported a position in IMNM in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.09M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • UBS AM held 188,636 shares of Immunome worth $4M as of Q2 2026.
  • UBS AM bought 1,625 Immunome shares in Q2 2026, an estimated $34.8K.
  • Immunome made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1717 holding.
  • UBS AM first reported a position in Immunome in Q1 2024 and has held it in 10 quarters since.
  • UBS AM's Immunome position peaked at $4.09M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.